Menu Close

Agendia

Agendia is a privately held, leading precision oncology company focused in breast cancer that develops and markets genomic diagnostic products, which help support physicians with their complex treatment decisions. Agendia’s breast cancer tests were developed using an unbiased gene selection by analyzing the complete human genome. The company’s offerings include the MammaPrint Breast Cancer Risk-of-Recurrence Test, and the BluePrint® Molecular Subtyping Test.

Agendia
Agendia
Agendia

ecosystem 

Life Sciences

location 

Amsterdam, Netherlands

investment / exit 

investment

website 

www.agendia.com

Other portfolio companies within life sciences